Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

OBJECTIVE: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Menopause
Autors principals: Greenspan, Susan L., Fitzpatrick, Lorraine A., Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C., Deal, Chad, Cosman, Felicia, McClung, Michael
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2020
Matèries:
Original Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://ncbi.nlm.nih.gov/pubmed/32665529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001593
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars